International Clinical Trial: A single-center, randomized, double-blind, placebo-controlled Phase IIa clinical study to evaluate the safety and efficacy of BGT-002 tablets as monotherapy in the treatment of mixed hyperlipidemia

Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2600115928) titled 'A single-center, randomized, double-blind, placebo-controlled Phase IIa clinical study to evaluate the safety and efficacy of BGT-002 tablets as monotherapy in the treatment of mixed hyperlipidemia' on Jan. 4.

Study Type: Interventional study

Study Design: Parallel

Primary Sponsor: Zhongshan Hospital, Fudan University

Condition: Dyslipidemia, MASLD

Intervention: BGT-002 group:BGT-002 tablets 200 mg, oral, BIW

Recruitment Status: Not Recruiting

Phase: 2

Date of First Enrollment: 2026-01-05

Target Sample Size: BGT-002 group:34;placebo group:34;

Countries of Recruitment: China

To know more, visit ht...